retatrutide mechanism clinical trials Retatrutide: Complete Triple Agonist Research Guide (2026) Retatrutide - Wikipedia

But honestly

If cardiovascular outcomes of tirzepatide are similar to GLP-1 RAs, the medication may be used by practitioners preferentially prior to using GLP-1 RAs in patients with or without diabetes who desire weight-loss

The most common retatrutide side effects are nausea (28%), diarrhea (24%), constipation (21%), and vomiting (17%), with symptoms peaking around weeks 6-8 before substantially improving by week 12

Community Insights Self-reported by pep-pedia.org users

There's no evidence saying these drugs cause C cell hyperplasia in humans, so the FDA gave it a black box warning until we know more

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: An integrated analysis of the DURATION trials